The CDMRP has launched an interactive Impactful Research Outcomes dashboard that serves as a resource for understanding how CDMRP supported research helps accelerate innovation, advance scientific knowledge, and ultimately improve the lives of service members, veterans, and the general public.

It highlights the results of research supported by CDMRP and focuses on what happens after research is funded. It shows how scientific discoveries progress over time—from early studies to clinical testing, new technologies, and approved treatments or tools used in patient care.

The Dashboard:

• Demonstrates research impact, showing how CDMRP funded projects contribute to meaningful clinical and translational advances.
• Highlights successful pathways from discovery to application, offering examples of how basic, translational, and clinical research come together over time.
• Supports transparency and accountability, helping funders, investigators, and the public understand how research dollars translate into health outcomes.
• Connects outcomes to specific research programs, making it easier to see how different disease focused programs contribute to progress across the medical research landscape.

Our thoughts - The CDMRP Impactful Research Outcomes dashboard is more than just informational and can be used toward strategic proposal development. At HJF, our team of experts can help you utilize the tool to ensure your proposals:

• Align with CDMRP priorities
• Demonstrate a compelling impact
• Present realistic pathways to translation
• Demonstrate awareness of program history and outcomes

Contact us to explore how we can meaningfully improve both the scientific positioning and the competitiveness of your proposal.

NEW! CDMRP released its pre-announcements for the Kidney Cancer Research Program and the Rare Cancers Research Program. Check out these and all the FY26 Funded Research Programs on CDMRP’s website.

On April 13, 2026, President Trump signed the Small Business Innovation and Economic Security Act (S. 3971), reauthorizing the SBIR/STTR programs through September 30, 2031, effectively ending the six-month lapse in authorization. Check out the full details on the current DoW opportunities listed below on the DoW SBIR/ STTR Innovation Portal.

Far Forward Manufacturing of CBRN Sensors

Objective: Accelerate Far Forward Manufacturing (FFM) of Chemical, Biological, Radiological, and Nuclear (CBRN) sensors. CBRN sensor products should be minimal size, weight, and power economic, while detecting and transmitting threat awareness in near real-time to the warfighter. The ability to create these devices on-demand and with limited logistical footprints will enable global operations and critical real-time data ingestion.

OPEN TOPIC - Tactical CB Visualization

Objective: A tactical tool or capability to increase situational awareness and enhance decision support of Warfighters operating in Chemical and Biological (CB) contested environments. The innovative technology proposed should work within Human Machine Interface (HMI) concepts to provide significant advantage compared to its size, weight, and power (SWAP) demands. This may include tactical augmented reality, sensor visualization solutions, or unique end user device/materials solutions. Shelf-Stable Nucleic Acid Synthesis Reagents for Field-Deployable Diagnostics Objective: Develop novel, shelf-stable reagents for nucleic acid synthesizers that enable the creation of high-quality oligonucleotides for rapid diagnostic test (RDT) development at the point of need in 30 days in a far-forward, expeditionary environment.

OPEN TOPIC - Expeditionary Biologics-on-Demand (BOND)

Objective: Develop a portable, high-performance BOND system for point-of-care protein production by maximizing protein purity, potency, and quality. This can be achieved through automated process control, incorporating soft sensors, machine learning, and real-time data analytics to predictively and autonomously adjust production parameters for optimal yield.

Microphysiological systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE)

Objective: Develop an immune microphysiological systems (iMPS) for the evaluation and development of vaccines against high consequence pathogens. iMPS may include, but are not limited to, immune organoid, organ-tissue equivalent, microfluidic chips, or similar systems as well as single or multiple organ models.

Novel Technologies for CWMD and Related Threats - Open Topic

Objective: Develop novel technologies with commercial and national security applications that enable the detection (or indication and warning) of radiological or nuclear threats without the need for bespoke sensors—using only signals from general-purpose military hardware, commercially-available devices proliferate in civil society, and publicly-available data sources.

Unbiased Behavioral Discovery Platforms

Objective: The DoD seeks to develop unguided behavioral discovery technologies to accelerate detection and medical countermeasure development against current and future threats. These platforms will enable:

1. Quantification of novel behaviors in pre-clinical animal models that are more sensitive than state-of-the-art.
2. High-throughput evaluation of intervention efficacy in animal models with high translational value.

RRPV 26-10-RAPID: Rapid Antibody Production for Immunoassay Diagnostics - This RPP seeks to support advanced research and development of rapid antibody and other protein-based molecular recognition reagent generation platforms to enable timely production of immunoassay-ready reagents for diagnostic use. The objective is to establish flexible, end-to-end systems capable of generating high-performance binders against known and emerging biological threats, with the goal of significantly compressing development timelines from pathogen sequence to assay-ready reagents—ideally within weeks. Holistic, end-to-end solutions are sought for this requirement.

Responses are due no later than Wednesday, May 13, 2026, at 1:00PM EST.

A Proposers Conference and Teaming Connect will be held on Monday, April 27 at 11:00AM EST.

Organizations interested in presenting their capabilities and teaming needs during the Teaming Connect may sign up. 

Slides from the session will be posted to the Teaming Page of the RRPV Members-Only site following the event. If you are unable to present but would still like to share your capabilities and teaming interests related to this RPP, you may submit a one-page capability and teaming statement to rrpv@ati.org for posting to the Teaming Page.

New Vaccine Platforms (NVP) - Coming Soon! The New Vaccine Platforms (NVP) Program aims to identify new vaccine platforms for the BARDA medical countermeasure (MCM) portfolio and advance them through a staged capability demonstration to identify technologies that (1) are safe; (2) are effective across multiple infectious disease threats from different pathogen families; and (3) enable efficient development and manufacturing.

RFI - Analytics Engine Platform – Due April 24, 2026 noon Eastern 

JPM CBRN Integrated Early Warning is developing AI/ML models to monitor physiological status, predict CBRN-related effects, and support Warfighter tactical decision making, readiness, and recovery. JPM CBRN Integrated Early Warning also seeks to develop a unified, open data architecture and algorithm ecosystem to standardize data collection, storage, and streamline the development, deployment, and sustainment of AI/ML

The Systematic Targeting of MicroPlastics (STOMP) program is a newly launched $144 million funding initiative from the Advanced Research Projects Agency for Health (ARPA H) focused on detecting, understanding, and ultimately removing microplastics and nanoplastics (MNPs) from the human body.

Microplastics are now known to accumulate in human organs—including lungs, blood vessels, and brain tissue, but there are currently no validated clinical tools to accurately measure an individual’s microplastic burden or determine which plastic types pose the greatest health risk. STOMP is intended to close this foundational gap and enable future medical and public health interventions.

STOMP is organized as a multi year-phased R&D program spanning three technical focus areas across two phases:

Phase 1 – Measurement and Biological Mechanisms

• Develop best in class laboratory methods capable of accurately detecting and characterizing nano scale microplastics in complex biological tissues
• Image and track microplastics in cells and organs to understand trafficking, accumulation, and toxicity mechanisms
• Establish standardized, reproducible measurement approaches that can serve as the scientific foundation for clinical use

Phase 2 – Translation and Removal

• Translate laboratory measurement techniques into affordable, scalable clinical systems for quantifying patient microplastic burden
• Leverage mechanistic insights to develop safe, effective strategies for removing microplastics from the human body
• Emphasize applicability to vulnerable populations, including pregnant individuals, children, patients with chronic disease, and highly exposed workers

Required Solution Summary Due: May 6, 2026 (5:00 PM ET)
Full Proposal Due: June 22, 2026 (5:00 PM ET

PCORI Cycle 2 funding is currently open. LOI responses are due by April 28, 2026.

The National Institutes of Health (NIH) Office of the Director has issued a Request for Information (RFI) seeking input to inform the development of the NIH-Wide Strategic Plan for Fiscal Years 2027–2031.

RFI Overview:

• Notice Number: NOT-OD-26-047
• Title: Request for Information: Inviting Comments and Suggestions on a Framework for the NIH-Wide Strategic Plan for FY 2027–2031
• Issued by: NIH Office of the Director
• Response Deadline: May 26, 2026 (11:59 PM ET)
• Submission: Electronic submission via NIH RFI portal (responses may be submitted anonymously)

Purpose:

The purpose of the NIH-Wide Strategic Plan is to communicate how NIH will advance its mission to support research in pursuit of fundamental knowledge about the nature and behavior of living systems, and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The updated plan will be submitted under requirements of the 21st Century Cures Act and is expected to be released in early FY2027. 

Important Notes:

• This RFI is for informational and planning purposes only and is not a current funding opportunity
• Submissions may be used by the government in future planning, reports, or solicitations
• Proprietary, confidential, or sensitive information should not be included
• Submission Deadline: All responses must be submitted by May 26, 2026 at 11:59 PM ET
• Inquiries: nihstrategicplan@od.nih.gov
• Link to RFI: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-26-047.html

New Funding Opportunities and Topic Ideas

Check these resources often for the latest:

• Explore NIH Grant Opportunities — Use the NIH-specific filters and Search Tips to identify funding opportunities in Grants.gov. Subscribe for new opportunities.
• Highlighted Topics — See selected research priority areas to consider for your next investigator-initiated application. Subscribe for new topics.
• Notices of New Policy Changes — Stay informed about updates to NIH policies, requirements, and guidance that may impact your application or award.